Here we describe an entirely new class of cell-penetrating peptide (CPP) represented by the short peptide Xentry (LCLRPVG) derived from an N-terminal region of the X-protein of the hepatitis B virus. Xentry permeates adherent cells using syndecan-4 as a portal for entry and is uniquely re...
a) Tail bleeding times, determined using the template method, in an allelic series of PI3KC2-deficient mice in the absence and presence of the anticoagulant, hirudin (5 mg kg À 1), and in WT mice treated with hirudin (5 mg kg À 1), aspirin (200 mg kg À 1) or both drugs...
[1] https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm [2] Goadsby; et al.(2017). "A Controlled Trial of Erenumab for Episodic Migraine". N.Engl. J. Med. (377:2123–2132). [3]https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604810.htm [4]...
Palynziq(Pegvaliase)是一种酶替代疗法,于2018年5月24日获批用于治疗苯丙酮尿症。Pegvaliase是一种重组聚乙二醇化的苯丙氨酸解氨酶突变蛋白(S503, S565)。最初由Ibex研发。 主要专利:WO 2006034373、WO 2009025760、WO 2011097335 12. Poteligeo Poteligeo(mogamulizumab-kpkc)于2018年8月8日获批,用于治疗复...
However, side effects from these drugs can be detrimental. In some of these cases, electrical stimulation can provide effective treatment of this pain without the drug-related side effects. A spinal cord stimulator is a device used to deliver pulsed electrical signals to the spinal cord to ...
Very often, on going activities are interrupted by the various emotional 'fallouts' created by adult controlled decisions that are not always as child focused as they could be. The ability and necessity to shift from one form of creating to another, while still holding them steady on their ...
Palynziq(Pegvaliase)是一种酶替代疗法,于2018年5月24日获批用于治疗苯丙酮尿症。Pegvaliase是一种重组聚乙二醇化的苯丙氨酸解氨酶突变蛋白(S503, S565)。最初由Ibex研发。 主要专利:WO 2006034373、WO 2009025760、WO 2011097335 12. Poteligeo Poteligeo(mogamulizumab-kpkc)于2018年8月8日获批,用于治疗复...
Design, Synthesis, and Antitumor Activity of 4-halocolchicines and Their Pro-drugs Activated by Cathepsin B. ACS Med. Chem. Lett. 2011, 2, 348–352. [Google Scholar] [CrossRef] [PubMed] [Green Version] Disclaimer/Publisher’s Note: The statements, opinions and data contained in all ...
Drugs that significantly increased cccDNA (mean fold-change > 3.5, n = 7) or reduced cccDNA accumulation (mean fold-change < 0.8, n = 10) relative to DMSO control in both HuH-7 and MCF-7 were selected for validation. * Clinical HBV therapeutics; # pre-clinical HBVCP inhibitors. (B) ...
0168-3659 J CONTROL RELEASE JOURNAL OF CONTROLLED RELEASE 药学 PHARMACOLOGY & PHARMACY 2 医学 2 1461-1457 INT J NEUROPSYCHOPH INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 精神病学 PSYCHIATRY 2 医学 2 1461-1457 INT J NEUROPSYCHOPH INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 临床神经学 CLINICAL NE...